Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 75,000 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Otto Klein sold 75,000 shares of Oruka Therapeutics stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the sale, the chief executive officer owned 925,580 shares of the company’s stock, valued at approximately $84,996,011.40. This represents a 7.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lawrence Otto Klein also recently made the following trade(s):

• On Monday, June 15th, Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.69, for a total transaction of $120,494.01.

Oruka Therapeutics Stock Down 0.6%

NASDAQ ORKA traded down $0.51 during trading hours on Tuesday, hitting $92.11. The company’s stock had a trading volume of 596,157 shares, compared to its average volume of 1,116,787. Oruka Therapeutics, Inc. has a twelve month low of $14.66 and a twelve month high of $115.51. The firm has a market capitalization of $6.10 billion, a P/E ratio of -45.37 and a beta of -0.34. The stock has a fifty day moving average of $94.75 and a 200 day moving average of $68.17.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, analysts predict that Oruka Therapeutics, Inc. will post -2.33 earnings per share for the current year.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ORKA. Sei Investments Co. raised its stake in Oruka Therapeutics by 136.0% during the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock worth $1,120,000 after buying an additional 13,164 shares during the period. Handelsbanken Fonder AB bought a new position in Oruka Therapeutics during the second quarter worth about $15,313,000. Dimensional Fund Advisors LP acquired a new position in Oruka Therapeutics in the first quarter valued at about $5,543,000. The Manufacturers Life Insurance Company grew its stake in Oruka Therapeutics by 18.3% in the first quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock valued at $3,559,000 after acquiring an additional 11,205 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Oruka Therapeutics in the first quarter worth about $1,811,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Guggenheim restated a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. UBS Group upped their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Finally, Wedbush reiterated an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.